MacCyte

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics. The company's core technology, the ExPERT™ platform, is based on proprietary flow electroporation for high-efficiency, low-toxicity transfection of a wide range of cell types. MaxCyte operates a partnership-driven business model, establishing Strategic Platform Licenses (SPLs) with numerous biotech and pharmaceutical companies, including Vertex Pharmaceuticals and CRISPR Therapeutics for the approved therapy CASGEVY. Additionally, the company has developed its own clinical-stage mRNA-based cell therapy platform, CARMA, focusing on solid tumors.